



Docket No.: 210740US0X

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

RE: Application Serial No.: 09/916,501

Applicants: Hans-Peter KRIMMER, et al.

Filing Date: July 30, 2001

For: PROCESS FOR THE PREPARATION OF ALLYSINE
ACETAL

Group Art Unit: 1652

Examiner: PATTERSON

SIR:

Attached hereto for filing are the following papers:

RESPONSE TO RESTRICTION REQUIREMENT (3 pp.)

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Vincent K. Shier, Ph.D.

Registration No. 50,552



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

03/26/2002 LSNEED 00000002 150030 09916501

01 FC:115 110.00 CH

#8 9/26/02



ATTORNEYS AT LAW

NORMAN F. OBLON
(703) 413-3000
NOBLON@OBLON.COM

VINCENT K. SHIER, PH.D.
REGISTERED PATENT AGENT
(703) 413-3000
VSHIER@OBLON.COM

DOCKET NO.: 210740US0X



#8

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Hans-Peter KRIMMER, et al.

: GROUP ART UNIT: 1652

SERIAL NO.: 09/916,501

:

FILED: JULY 30, 2001

: EXAMINER: PATTERSON

FOR: PROCESS FOR THE PREPARATION OF ALLYSINE ACETAL

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated August 21, 2002, Applicants elect, with traverse, Group I, Claims 1-10, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

Group I: Claims 1-10, drawn to a process for producing an allysine acetal; and

Group II: Claim 11, drawn to a method for producing a pharmaceutical or biologically active product using an acetal.

Applicants elect, with traverse, Group I, Claims 1-10.

Applicants note that claims of Group II directly depend on Group I and as such can not be separated.

In regard to Groups I and II, the Office has characterized the relationship between these two groups as "mutually exclusive and patentably distinct." However, the Office merely states this conclusion without providing any reasonable basis to support this assertion. In fact, when attempting to demonstrate distinctness the Office states that "[Group II] reads